4893 Noile-Immune Biotech
- 128
- -6-4.48%
Noile-Immune Biotech News
Volume change rate ranking (10:00) ~ Neil Immune, Metaplanet, etc. are ranked
* In the volume change rate ranking, it is possible to know the interest of market participants, such as shopping trends, by comparing the average turnover for the last 5 days with the turnover on the day of distribution. ■Top Volume Change Rate [5/21 10:32 as of 10:32] (Last 5 Day Average Volume Comparison) Stock Code Stock Name Volume 5 Day Average Volume Volume Change Rate Stock Price Change Rate ＜4893＞ Neulimune 860600 20232.2 202.61% -0.006
Noile-Immune Biotech: Confirmation
Noile-Immune Biotech: Quarterly Report - 10th Quarter 1st Quarter (2024/01/01 - 2024/03/31)
Noile-Immune Biotech: Summary of financial results for the 1st quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
The TSE Growth Index continues to rise, and although sales continue to be weak, buybacks take precedence
TSE Growth Market Index 830.23 +4.39/ Volume 72.93 million shares/ trading price 77.8 billion yen TSE Growth Market 250 Index 647.40 +2.79/ turnover 44.77 million shares/ trading price 54.7 billion yen Today's growth market continues to grow with both the TSE Growth Market Index and the TSE Growth Market 250 Index. The number of rising stocks is 322, the number of falling stocks is 214, and 37 unchanged. The US stock market continued to rise on the 29th. The Dow Jones Industrial Average rose by $146.43 (+ 0.38%)
Neurimune, etc. [strange brands seen from changes in trading volume]
Stock closing price turnover compared to the previous day*＜4893＞Neil Immune 173 12 12164900*＜6822＞Oi Electric 2021 180 91000*＜4558＞Chukyo Pharmaceutical 209 2 152400*＜4772＞Stream M 136 0 1651800*＜1867＞Ueki Gumi 1626 47 126900*＜15
3 points to pay attention to in the backstage -- strong wait-and-see attitude ahead of announcing the results of the Bank of Japan meeting
I would like to pay attention to the following 3 points in the late-day transaction on the 26th. ・The Nikkei Average rebounded, waiting to announce the results of the Bank of Japan meeting and the Nikkei Average rebelled against a strong wait-and-see attitude · The dollar and yen are fighting, the Bank of Japan is awaiting policy announcements and the top contributor to price increases is Tokyo Electron ＜8035＞, the same 2nd place is SoftBank G＜9984＞■The Nikkei Average rebounds against a strong wait-and-see attitude ahead of announcing the results of the Bank of Japan meeting. 37780.35 yen (estimated turnover 70,400 million), 151.87 yen higher (+0.40%) compared to the previous day
Front market for high stop and low stop stocks
■Stop High＜4893＞Neurimune Biotech ＜5026＞Triple Eyes ■Low Stop ＜6617＞Toko Takaoka ※Includes temporary stop high/low (indicative value)
Jefferies Adjusts Noile-Immune Biotech's Price Target to 440 Yen From 800 Yen, Keeps at Buy
04:37 AM EST, 12/19/2023 (MT Newswires) -- Jefferies Adjusts Noile-Immune Biotech's Price Target to 440 Yen From 800 Yen, Keeps at Buy
Japanese Shares Hit 33,000 Mark Again as Yen Slips, BoJ Holds Rates Steady
Japanese shares reached the 33,000 mark again on Tuesday, buoyed by a decline in the yen after the Bank of Japan held the benchmark rate steady. Closing at 33,219.39, the Nikkei 225 advanced 1.4%, or
Noile-Immune Biotech to Seek New Partnerships After Termination of Takeda License Deal; Shares Surge 23%
Noile-Immune Biotech (TYO:4893) plans to seek new partnerships and explore drug development strategies for its solid tumor treatment candidates, NIB102 and NIB103, after its licensee Takeda Pharmaceut
Noile-Immune Biotech Regains Rights to Solid Tumor Drug Candidates as Takeda Terminates License Deal
Noile-Immune Biotech (TYO:4893) regained the development and commercialization rights to solid tumor treatment candidates, NIB102 and NIB103, after its licensee Takeda Pharmaceutical (TYO:4502) termin
Analysis
Price Target
No Data
